Evolus Stock Forecast, Price & News

10 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last year. There are currently 1 sell rating, 4 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Evolus stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EOLS, but not buy additional shares or sell existing shares.
View analyst ratings for Evolus or view top-rated stocks.

Wall Street analysts have given Evolus a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Evolus wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Evolus is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Evolus.

Evolus, Inc. (NASDAQ:EOLS) posted its quarterly earnings data on Thursday, October, 29th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.40) by $0.06. The company had revenue of $17.66 million for the quarter, compared to analyst estimates of $12.40 million. Evolus had a negative trailing twelve-month return on equity of 121.11% and a negative net margin of 120.63%.
View Evolus' earnings history.

Evolus' stock was trading at $5.91 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, EOLS stock has increased by 89.3% and is now trading at $11.19.
View which stocks have been most impacted by COVID-19.

Evolus issued an update on its FY 2020 Pre-Market earnings guidance on Tuesday, February, 23rd. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $56.5-56.5 million, compared to the consensus revenue estimate of $58.37 million.

10 Wall Street analysts have issued 12-month price targets for Evolus' shares. Their forecasts range from $5.00 to $25.00. On average, they anticipate Evolus' stock price to reach $13.00 in the next twelve months. This suggests a possible upside of 16.2% from the stock's current price.
View analysts' price targets for Evolus or view top-rated stocks among Wall Street analysts.

1 employees have rated Evolus CEO David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among Evolus' employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Evolus include Praxis Precision Medicines (PRAX), Olema Pharmaceuticals (OLMA), MacroGenics (MGNX), Kiniksa Pharmaceuticals (KNSA), uniQure (QURE), Five Prime Therapeutics (FPRX), Antibe Therapeutics (ATBPD), COMPASS Pathways (CMPS), Antibe Therapeutics (ATBPD), Ocular Therapeutix (OCUL), Cytokinetics (CYTK), Nkarta (NKTX), DiaMedica Therapeutics (DMCAF), Supernus Pharmaceuticals (SUPN) and Zealand Pharma A/S (ZEAL).
View all of EOLS's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evolus investors own include 76837 (CGI), ADMA Biologics (ADMA), Chesapeake Energy (CHKAQ), Matinas BioPharma (MTNB), Advanced Micro Devices (AMD), Dynavax Technologies (DVAX), Sorrento Therapeutics (SRNE), Aldeyra Therapeutics (ALDX), OrganiGram (OGI) and Bionano Genomics (BNGO).

(EOLS) raised $65 million in an initial public offering on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Evolus' stock is owned by a variety of institutional and retail investors. Top institutional investors include BlackRock Inc. (4.39%), Northern Trust Corp (0.81%), Renaissance Technologies LLC (0.75%), Citigroup Inc. (0.33%), Squarepoint Ops LLC (0.29%) and Nuveen Asset Management LLC (0.25%). Company insiders that own Evolus stock include Corp Alphaeon, David N Gill, Kristine Romine, Lauren P Silvernail, Rui Avelar, Simone Blank and Vikram Malik.
View institutional ownership trends for Evolus.

EOLS stock was sold by a variety of institutional investors in the last quarter, including BlackRock Inc., LPL Financial LLC, Northern Trust Corp, Bank of New York Mellon Corp, and Nuveen Asset Management LLC.
View insider buying and selling activity for Evolus or view top insider-selling stocks.

EOLS stock was acquired by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Squarepoint Ops LLC, SG Americas Securities LLC, JPMorgan Chase & Co., CM Management LLC, Virtu Financial LLC, Citigroup Inc., and Hsbc Holdings PLC. Company insiders that have bought Evolus stock in the last two years include David N Gill, Kristine Romine, Simone Blank, and Vikram Malik.
View insider buying and selling activity for Evolus or or view top insider-buying stocks.

Shares of EOLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EOLS stock can currently be purchased for approximately $11.19.

Evolus has a market capitalization of $377.65 million and generates $34.92 million in revenue each year. The company earns $-90,030,000.00 in net income (profit) each year or ($3.19) on an earnings per share basis.

Evolus employs 125 workers across the globe.

The official website for Evolus is www.evolus.com.

Evolus is headquartered at 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660.

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The company can be reached via phone at 949-284-4555 or via email at [email protected]